bortezomib waverley 3.5 mg powder for solution for injection
waverley pharma europe limited - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib
bortezomib medac 3.5 mg powder for solution for injection
medac gesellschaft für klinische spezialpräparate mbh - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib
bortezomib koanaa 3.5 mg powder for solution for injection
koanaa healthcare limited - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib
bortezomib mylan 3.5 mg powder for solution for injection
mcdermott laboratories ltd., t/a gerard laboratories - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib
bortez teva 3.5 mg
abic marketing ltd, israel - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - bortezo teva is indicated for the treatment of patients with multiple myeloma. bortezo teva is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezo teva in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
velcade 3.5 mg
j-c health care ltd - bortezomib - powder for solution for injection - bortezomib 3.5 mg - bortezomib - velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma.velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
bortezom bortezomib 3.5 mg powder for injection vial
pharmacor pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; tert-butyl alcohol - bortezom in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezom as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezom is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezom in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.
bortezomib medomie
medomie pharma ltd, israel - bortezomib - powder for solution for injection - bortezomib 3.5 mg/vial - bortezomib - bortezomib medomie for injection is indicated for the treatment of patients with multiple myeloma.bortezomib medomie for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. bortezomib medomie in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
bortezomib eg 2.5 mg/ml inj. sol. s.c./i.v. vial
eg sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 2,5 mg/ml - solution for injection - bortezomib
bortezomib reddy 3.5 mg inj. sol. (pwdr.) s.c./i.v. vial
reddy holding gmbh - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - bortezomib